Value
6.0/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 1.4 |
| Analyst target | 9.0 |
ARWR · Why this verdict
Why Arrowhead Pharmaceuticals (ARWR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Arrowhead is a high-growth biotech (171% YoY revenue growth, 56.4% upside to the $93.71 analyst target) that is still cash-burning and reliant on a single approved product, so the recovery setup carries binary risk with earnings due in 23 days.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing 171% YoY, with the Rule of 40 reading at an elite 164 and an industry growth leader ranking among peers. Growth breakdown | Revenue growth should remain above 50% YoY and quarterly revenue should hold near the $60M-$75M range seen in recent quarters. | →Stable |
| CounterRevenue is extremely lumpy (from $542.7M in March 2025 to $27.8M in June 2025 to $75.3M in June 2026), so the headline growth rate reflects milestone timing, not durable recurring sales. | ||
The company is cash-burning with free cash flow at -7% of revenue, a manageable drain that the large revenue base can fund. Quality breakdown | Free cash flow should move toward breakeven, staying better than -15% of revenue over the next 12 months. | →Stable |
| CounterReturn on equity, return on assets and net margin all score 0.0, and EPS of -1.36 in the latest quarter shows losses are widening, not narrowing. | ||
Revenue concentration in a single approved product means the growth story depends on that product continuing to sell at the current pace. Bear case | Quarterly revenue should stay above the $60.4M next-quarter estimate as the approved product scales. | ↓Deteriorating |
| CounterWith a single approved product and debt-to-equity of 3.0 triggering a leverage penalty, any safety, competitive or reimbursement setback hits the whole business at once. | ||
Price is 56.4% below the $93.71 analyst target while downside to the stop is only 7.7%, a reward-to-risk of 7.33. Estimated upside | The analyst target should stay near $93.71 or higher while the price recovers from $59.90. | →Stable |
| CounterAnalyst targets for a loss-making biotech often assume milestone success, and earnings results have been mixed with 2 misses and 2 beats in the last 4 quarters. | ||
Despite a death cross, the MACD is improving and RSI is 47, a recovery setup with rising on-balance volume (accumulation). Chart pattern detection | Price should hold above the $55.71 stop and momentum should stay above 5.0/10 as the recovery develops. | →Stable |
| CounterThe stock remains below its 200-day average with a confirmed downtrend, and volume on up-days is weak at a 0.9 volume score. | ||
Revenue is growing 171% YoY, with the Rule of 40 reading at an elite 164 and an industry growth leader ranking among peers.
→StableGrowth breakdown
- Expectation
- Revenue growth should remain above 50% YoY and quarterly revenue should hold near the $60M-$75M range seen in recent quarters.
CounterRevenue is extremely lumpy (from $542.7M in March 2025 to $27.8M in June 2025 to $75.3M in June 2026), so the headline growth rate reflects milestone timing, not durable recurring sales.
The company is cash-burning with free cash flow at -7% of revenue, a manageable drain that the large revenue base can fund.
→StableQuality breakdown
- Expectation
- Free cash flow should move toward breakeven, staying better than -15% of revenue over the next 12 months.
CounterReturn on equity, return on assets and net margin all score 0.0, and EPS of -1.36 in the latest quarter shows losses are widening, not narrowing.
Revenue concentration in a single approved product means the growth story depends on that product continuing to sell at the current pace.
↓DeterioratingBear case
- Expectation
- Quarterly revenue should stay above the $60.4M next-quarter estimate as the approved product scales.
CounterWith a single approved product and debt-to-equity of 3.0 triggering a leverage penalty, any safety, competitive or reimbursement setback hits the whole business at once.
Price is 56.4% below the $93.71 analyst target while downside to the stop is only 7.7%, a reward-to-risk of 7.33.
→StableEstimated upside
- Expectation
- The analyst target should stay near $93.71 or higher while the price recovers from $59.90.
CounterAnalyst targets for a loss-making biotech often assume milestone success, and earnings results have been mixed with 2 misses and 2 beats in the last 4 quarters.
Despite a death cross, the MACD is improving and RSI is 47, a recovery setup with rising on-balance volume (accumulation).
→StableChart pattern detection
- Expectation
- Price should hold above the $55.71 stop and momentum should stay above 5.0/10 as the recovery develops.
CounterThe stock remains below its 200-day average with a confirmed downtrend, and volume on up-days is weak at a 0.9 volume score.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 7.1 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -7% of revenue
- ▸Rule of 40: 164 (elite)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 171% YoY
Momentum
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 3.8 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -1.4%/30d — confirmed downtrend
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.9 |
| Analyst rating | 8.6 |
| Price target | 9.9 |
- ▸Analyst upside: 87%
Insider
4.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 4.4 |
| notable moves | 3.0 |
- ▸Insider selling (low materiality) — $1,186,600 (0.014% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.9 |
| quality rank | 2.1 |
| growth rank | 8.9 |
- ▸Industry growth leader
Technical
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.7 |
| support resistance | 7.7 |
| 52w position | 2.0 |
Risk (lower is worse)
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.6 |
| days to cover | 6.2 |
| volatility | 2.4 |
| put call | 5.1 |
| implied vol | 1.2 |
| max pain risk | 7.0 |
| beta | 5.5 |
| debt equity | 2.0 |
| news risk | 5.5 |
- ▸High IV: 73%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 7 days
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- ASYMMETRY:7.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:4.1<4.5
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:7d<=7d
Warning (0)
none
Reward-to-Risk
7.83
Upside
+63.1%
Downside
8.1%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 56
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:4.1<4.5, DEATH_CROSS:HARD_BLOCK, EARNINGS_PROXIMITY:7d<=7d) reinforce the read. Current asymmetry R:R is 7.83 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Sentiment at 8.1, and Catalyst at 6.3; the weakest are Peer rank at 3.8, Insider at 4.1, and Momentum at 4.1. The V9 engine flagged 3 failed gates, producing an asymmetric reward-to-risk of 7.83 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Explosive Revenue Growth
Trip ifRevenue growth falls below 50% YoY from current 171%.
- P2Modest Cash Burn
Trip ifFree cash flow falls below -25% of revenue from current -7%.
- P3Single Product Dependence
Trip ifQuarterly revenue falls below $60M for 2 consecutive quarters.
- P4Large Analyst Upside
Trip ifAnalyst target falls below $70 from current $93.71.
- P5Recovery Setup After Death Cross
Trip ifShare price falls below $55.71 from current $59.90.